Research programme: phospholipid drug conjugates - Cellectar Biosciences
Latest Information Update: 15 Dec 2023
At a glance
- Originator Cellectar Biosciences
- Class Antineoplastics; Drug conjugates; Phospholipid ethers; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 12 Dec 2023 Cellectar Biosciences receives Notice of Allowance for phospholipid drug conjugates from the Japanese, Chinese, Eurasian, Brazilian, and Mexican patent authorities
- 13 Jul 2021 Cellectar Biosciences in-licenses OHPAS linker chemistry technology from IntoCell
- 13 Jul 2021 Preclinical trials in Cancer in USA